for which confidential treatment by the Commission is properly sought will be treated accordingly. A redacted nonconfidential version of the document must also be filed simultaneously with the any confidential filing. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.

This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of sections 201.10 and 210.50 of the Commission's Rules of Practice and Procedure (19 CFR 201.10, 210.50).

By order of the Commission. Issued: July 25, 2012.

## Lisa R. Barton,

Acting Secretary to the Commission. [FR Doc. 2012–18596 Filed 7–30–12; 8:45 am] BILLING CODE 7020–02–P

## DEPARTMENT OF JUSTICE

## Notice of Lodging of Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act

Notice is hereby given that on July 25, 2012, a proposed Consent Decree in *United States v. James W. Clark, et al.,* Civil Action No. 08–CV–04158, was lodged with the United States District Court for the Northern District of Illinois.

In this action, the United States brought claims against Calumet Heat Treating Company, Thomas G. Cooper, and Nitrex, Inc. ("Settling Defendants") for response costs associated with the release or threatened release of hazardous substances from facilities at and near the South Green Plating Superfund Site in Chicago, Illinois (hereinafter the "Site"), pursuant to the Comprehensive Environmental Response, Compensation, and Liability Act, 42 U.S.C. 9601 et seq. ("CERCLA"). The proposed Consent Decree requires Settling Defendants to reimburse the United States' past response costs in the amount of \$430,000.00.

The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and either emailed to *pubcomment-ees.enrd@usdoj.gov* or mailed to P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611, and should refer to *United States* v. *James W. Clark, et al.,* Civil Action No. 08–CV–04158 (N.D. Ill.), D.J. Ref. No. 90–11–3–09477.

During the public comment period, the Consent Decree may be examined on the following Department of Justice Web site: http://www.usdoj.gov/enrd/ Consent Decrees.html. A copy of the Consent Decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044-7611 or by faxing or emailing a request to **Environment and Natural Resources** Division, Environmental Enforcement Section, fax no. (202) 514-0097, phone confirmation number (202) 514-5271, email EESCDCopy.ENRD@usdoj.gov. If requesting a copy from the Consent Decree Library, please enclose a check in the amount of \$5.50 for a copy of the complete Consent Decree (25 cents per page reproduction cost) payable to the U.S. Treasury or, if by email or fax, forward a check in that amount to the Consent Decree Library at the stated address.

#### Maureen Katz,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2012–18517 Filed 7–30–12; 8:45 am] BILLING CODE 4410–15–P

## DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Application; Wildlife Laboratories Inc.

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 21, 2012, Wildlife Laboratories Inc., 1230 W. Ash Street, Suite D, Windsor, Colorado 80550, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Carfentanil (9743), a basic class of controlled substance listed in schedule II.

The company plans to manufacture the above listed controlled substance for sale to veterinary pharmacies, zoos, and for other animal and wildlife applications.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 1, 2012.

Dated: April 17, 2012.

## Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012–18630 Filed 7–30–12; 8:45 am] BILLING CODE 4410–09–P

BILLING CODE 4410-09-P

# DEPARTMENT OF JUSTICE

## **Office of Justice Programs**

[OJP (NIJ) Docket No. 1600]

## Guidelines for Cases Requiring On-Scene Death Investigation

**AGENCY:** National Institute of Justice, Justice.

**ACTION:** Notice and request for comments.

SUMMARY: In an effort to obtain comments from interested parties, the U.S. Department of Justice, Office of Justice Programs, National Institute of Justice, Scientific Working Group for Medicolegal Death Investigation will make available to the general public a draft document entitled, "Guidelines for Cases Requiring On-Scene Death Investigation". The opportunity to provide comments on this document is open to coroner/medical examiner office representatives, law enforcement agencies, organizations, and all other stakeholders and interested parties. Those individuals wishing to obtain and provide comments on the draft document under consideration are directed to the following link: http:// swgmdi.org/index.php?option=com content&view=article&id=85& Itemid=102.

**DATES:** Comments must be received on or before August 22, 2012.

#### FOR FURTHER INFORMATION CONTACT:

Patricia Kashtan, by telephone at 202– 353–1856 [Note: this is not a toll-free telephone number], or by email at *Patricia.Kashtan@usdoj.gov.* 

## John Laub,

Director, National Institute of Justice. [FR Doc. 2012–18623 Filed 7–30–12; 8:45 am] BILLING CODE 4410–18–P